MeiraGTx Holdings
MGTX
10.82
+0.22
+2.08%
MeiraGTx Holdings
US · MGTX
#3220 by market cap
Listed 2018
10.82
+0.22
+2.08%
Live - 5344 symbols - heartbeat 307s ago
· 2026-10-08 08:05
Pre-market
11.00
+1.71%
After-hours
10.82
0.00%
- Market cap
- 1.04B
- P/E (TTM)i
- 12.44
- P/Bi
- 4.82
- EPSi
- -1.42
- Div yieldi
- 0.00%
- 52W posi
- 48%
Reader sentiment
Are you bullish or bearish on MGTX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -3.43, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +144.57% YoY
Margins
- Gross margin
- 94.05%
- Operating margin
- -130.20%
- Net margin
- -140.31%
Key ratios & quality
- Enterprise valuei
- 1.05B
- Altman Z-Scorei
- -3.43
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 13.29M | 15.56M | 37.70M | 15.92M | 14.02M | 33.28M | 81.39M |
| Gross profit | -- | -- | -- | -- | -- | 14.02M | 9.49M | 76.55M |
| Selling & admin expenses | 44.48M | 46.68M | 44.21M | 43.77M | 46.55M | 47.29M | 54.22M | 52.90M |
| Research & development | 33.62M | 24.88M | 33.91M | 66.69M | 85.73M | 103.79M | 119.48M | 129.62M |
| Operating profit | -78.10M | -58.27M | -62.55M | -72.76M | -116.36M | -137.06M | -164.21M | -105.97M |
| Pretax profit | -83.34M | -54.75M | -57.99M | -79.56M | -129.62M | -84.03M | -147.79M | -114.20M |
| Tax | -474.39K | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -82.87M | -54.75M | -57.99M | -79.56M | -129.62M | -84.03M | -147.79M | -114.20M |
| Basic EPS | -4 | -2 | -2 | -2 | -3 | -1 | -2 | -1 |
| Diluted EPS | -4.47 | -1.65 | -1.54 | -1.80 | -2.87 | -1.49 | -2.12 | -1.42 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.93M | 3.69M | 410.00K | 75.36M | 293.00K | 321.43M |
| Gross profit | 548.00K | 1.02M | 97.00K | 74.89M | 95.00K | 314.27M |
| Selling & admin expenses | 9.36M | 12.31M | 13.62M | 17.60M | 8.93M | 12.01M |
| Research & development | 32.78M | 33.50M | 32.53M | 30.81M | 31.98M | 57.83M |
| Operating profit | -41.60M | -44.79M | -46.05M | 26.47M | -40.82M | 244.43M |
| Pretax profit | -39.98M | -38.80M | -50.51M | 15.09M | -46.31M | 163.03M |
| Tax | -- | 0 | -- | -- | -- | 2.36M |
| Net profit | -39.98M | -38.80M | -50.51M | 15.09M | -46.31M | 160.67M |
| Basic EPS | -1 | 0 | -1 | 0 | -1 | 2 |
| Diluted EPS | -0.51 | -0.48 | -0.62 | 0.19 | -0.57 | 1.71 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 74.65M | 268.98M | 272.58M | 183.24M | 154.34M | 159.62M | 123.52M | 91.76M |
| Cash & ST investments | 68.08M | 227.23M | 209.52M | 137.70M | 115.52M | 129.57M | 103.66M | 65.93M |
| Inventory | -- | -- | -- | -- | -- | 0 | 385.00K | 0 |
| Total assets | 96.89M | 323.89M | 363.70M | 320.16M | 318.24M | 326.74M | 269.75M | 244.43M |
| Total current liabilities | 15.50M | 49.20M | 54.15M | 68.13M | 82.07M | 67.08M | 60.78M | 122.56M |
| Short-term debt | 27.20K | 1.67M | 2.58M | 3.37M | 3.88M | 4.19M | 4.05M | 27.54M |
| Long-term debt | -- | -- | -- | -- | 71.03M | 72.12M | 73.22M | 49.69M |
| Total liabilities | 15,835,290.00 | 133,085,545.00 | 125,138,000.00 | 134,763,000.00 | 200,499,000.00 | 188,567,000.00 | 201,924,000.00 | 250,223,000.00 |
| Total equity | 81.06M | 190.80M | 238.56M | 185.40M | 117.74M | 138.18M | 67.83M | -5.79M |
| Retained earnings | -148.29M | -203.04M | -261.03M | -340.59M | -470.20M | -554.23M | -702.02M | -816.22M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 79.89M | 47.08M | 34.17M | 91.76M | 96.20M | 218.35M |
| Cash & ST investments | 66.52M | 32.17M | 14.84M | 65.93M | 71.54M | 143.17M |
| Inventory | 607.00K | 314.00K | 0 | 0 | -- | -- |
| Total assets | 224.01M | 198.72M | 189.47M | 244.43M | 244.66M | 396.45M |
| Total current liabilities | 52.37M | 53.44M | 152.92M | 122.56M | 176.13M | 58.10M |
| Short-term debt | 3.30M | 2.65M | 76.53M | 27.54M | 27.13M | 2.30M |
| Long-term debt | 73.50M | 73.77M | -- | 49.69M | 49.70M | 100.00M |
| Total liabilities | 190,915,000.00 | 195,756,000.00 | 230,028,000.00 | 250,223,000.00 | 302,785,000.00 | 180,668,000.00 |
| Total equity | 33.10M | 2.96M | -40.56M | -5.79M | -58.13M | 215.78M |
| Retained earnings | -742.00M | -780.80M | -831.31M | -816.22M | -862.54M | -701.82M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -58.89M | 20.04M | -63.97M | -10.53M | -73.10M | -105.37M | -104.50M | -46.36M |
| Depreciation & amortization | 2.05M | 2.24M | 4.17M | 7.87M | 8.60M | 13.72M | 12.68M | 12.61M |
| Free cash flow | -70.15M | 11.06M | -100.99M | -65.75M | -118.06M | -125.54M | -109.45M | -50.60M |
| Dividends paid | -- | -- | -- | 0 | -- | -- | -- | -- |
| Stock buybacks / issuance | 69.75M | 155.20M | 87.05M | 0 | 25.00M | 91.95M | 59.39M | 15.07M |
| Ending cash balance | 68.20M | 227.36M | 209.52M | 137.70M | 115.52M | 130.65M | 105.67M | 68.19M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -36.83M | -43.95M | -12.22M | 46.63M | 17.81M | -38.54M |
| Depreciation & amortization | 3.08M | 3.19M | 3.16M | 3.18M | 3.01M | 2.82M |
| Free cash flow | -38.54M | -45.18M | -12.83M | 45.95M | 15.55M | -62.85M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 4.48M | 5.43M | 0 | 5.16M | -4.17M | 114.18M |
| Ending cash balance | 68.61M | 34.42M | 17.11M | 68.19M | 73.76M | 145.37M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -502.59 | -40.28 | -27.01 | -37.53 | -85.52 | -65.67 | -143.48 | -368.19 |
| ROA %i | -137.96 | -26.02 | -16.87 | -23.27 | -40.61 | -26.06 | -49.55 | -44.42 |
| ROIC %i | -480.72 | -37.33 | -24.91 | -33.83 | -59.86 | -33.40 | -72.97 | -88.17 |
| 5-year avg ROE %i | -- | -- | -- | -- | -138.59 | -51.20 | -71.84 | -140.08 |
| EBIT margin %i | -- | -411.51 | -371.73 | -210.27 | -783.10 | -504.97 | -404.22 | -125.33 |
| FCF / sales %i | -- | 83.24 | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.82 | 5.47 | 5.03 | 2.69 | 1.88 | 2.38 | 2.03 | 0.75 |
| Quick ratioi | 4.61 | 5.34 | 4.82 | 2.54 | 1.76 | 2.28 | 1.88 | 0.69 |
| Debt / assetsi | 0.04 | 7.16 | 6.12 | 7.41 | 28.99 | 27.32 | 31.44 | 36.28 |
| LT debt / equityi | 0.01 | 11.27 | 8.24 | 10.98 | 75.05 | 61.57 | 119.04 | -- |
| Interest coveragei | -2,492.05 | -1,125.19 | -415.60 | -275.25 | -25.21 | -5.34 | -10.14 | -8.36 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | 6.20 | -3.43 | -4.07 | 72.27 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -216.14 | -379.53 | -611.42 | -368.19 | -- | 72.28 |
| ROA %i | -62.76 | -67.69 | -69.00 | -44.42 | -51.44 | 26.54 |
| ROIC %i | -97.68 | -118.12 | -138.02 | -88.17 | -- | 42.47 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -447.04 | -381.52 | -569.48 | -125.33 | -136.08 | 23.59 |
| FCF / sales %i | -- | -- | -- | -- | 4.38 | -- |
| Current ratioi | 1.53 | 0.88 | 0.22 | 0.75 | 0.55 | 3.76 |
| Quick ratioi | 1.37 | 0.73 | 0.17 | 0.69 | 0.51 | 3.23 |
| Debt / assetsi | 36.10 | 40.49 | 46.48 | 36.28 | 35.78 | 28.33 |
| LT debt / equityi | 234.39 | 2,629.12 | -- | -- | -- | 51.04 |
| Interest coveragei | -11.81 | -11.26 | -12.44 | -8.36 | -9.04 | 7.52 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development and manufacturing of genetic medicines100.00%
Quote time 2026-10-08 08:05:28 · For reference only, not investment advice and not tailored to your situation.